Overview

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Status:
Completed
Trial end date:
2019-03-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Liraglutide